Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction

William E. Boden, Seth Baum, Peter P. Toth, Sergio Fazio, Deepak L. Bhatt

    Research output: Contribution to journalReview articlepeer-review

    1 Scopus citations

    Fingerprint

    Dive into the research topics of 'Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction'. Together they form a unique fingerprint.

    Medicine & Life Sciences